ERBB3 and neoplasm: We further showed that the ErbB3-suppressive and CD8+ T-cell–inflamed tumor microenvironments of MAPK pathway mutant HNSCC tumors are likely two independent molecular characteristics of MAPK-mutated HNSCC patients with remarkably improved outcomes.